Stockscreener 앱 받기
103.10
1.07%
1.09
시간 외 거래:
103.10
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
Why Mirum Pharmaceuticals Inc. stock is trending among retail traders - mfd.ru
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Embodies the Minervini Growth Momentum Strategy - ChartMill
What are analysts’ price targets for Mirum Pharmaceuticals Inc.Earnings Summary Report & Weekly Sector Rotation Insights - mfd.ru
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Will Mirum Pharmaceuticals Inc. benefit from AI trendsShare Buyback & Expert Verified Stock Movement Alerts - mfd.ru
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The National Law Review
Mirum Pharmaceuticals Grants Stock Awards to New Employees - Intellectia AI
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Offers a High-Growth Momentum and Technical Breakout Setup - ChartMill
Candriam S.C.A. Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A Biotech Gem with 14% Upside Potential - DirectorsTalk Interviews
Mirum Pharmaceuticals expands portfolio in rare disease drug focus - Traders Union
Gap Down: Can Mirum Pharmaceuticals Inc benefit from deglobalizationJuly 2025 PreEarnings & Fast Entry Momentum Alerts - baoquankhu1.vn
Health Canada approves Livmarli for PFIC and ALGS - The Pharma Letter
Mirum Pharmaceuticals, Inc. $MIRM Shares Purchased by Penserra Capital Management LLC - MarketBeat
Sentiment Review: Is Mirum Pharmaceuticals Inc a turnaround storyFed Meeting & Safe Entry Trade Signal Reports - baoquankhu1.vn
Health Canada LIVMARLI Decision And Bluejay Deal Shape Mirum Outlook - Yahoo Finance
Mirum Pharmaceuticals says Health Canada authorizes Livmarli for cholestatic pruritus in progressive familial intrahepatic cholestasis (PFIC) patients - marketscreener.com
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome - BioSpace
Mirum Pharmaceuticals Stumbles on Health Canada Approval - Baystreet.ca
Mirum Pharmaceuticals' Tablet Formulation of its Cholestasic Pruritus Treatment Livmarli Approved in Canada - marketscreener.com
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) - Yahoo Finance
Is Mirum Pharmaceuticals on a Strong Path to Profitability? - AOL.com
Hot Picks: Small-cap pharma stocks in focus as key drug approvals near - BNN Bloomberg
Mirum Pharmaceuticals (MIRM) Price Target Increased by 10.50% to 116.99 - Nasdaq
Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $940,856.40 in Stock - MarketBeat
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $99,994.40 in Stock - MarketBeat
Howe Jolanda, SVP at Mirum Pharmaceuticals, sells $99997 in Mirm stock By Investing.com - Investing.com South Africa
Howe Jolanda, SVP at Mirum Pharmaceuticals, sells $99997 in Mirm stock - Investing.com Australia
Mirum Pharma president & COO sells $271k in stock - Investing.com
Mirum Pharma president & COO sells $271k in stock By Investing.com - Investing.com India
Mirum Pharma CEO Peetz sells $941k in shares By Investing.com - Investing.com UK
Mirum Pharmaceuticals, Inc. (MIRM): Investor Outlook on a Biotech with a 10.5% Upside Potential - DirectorsTalk Interviews
Y Intercept Hong Kong Ltd Takes Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum doubles down on diversified rare disease strategy - PharmaVoice
Mirum Pharmaceuticals stock hits all-time high at 103.94 USD By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 12-Month High Following Analyst Upgrade - MarketBeat
Mirum Pharmaceuticals stock hits all-time high at 103.94 USD - Investing.com
Top 3 Health Care Stocks That May Implode In Q1 - Benzinga
Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by Atle Fund Management AB - MarketBeat
Is Mirum Pharmaceuticals on a Strong Path to Profitability? - The Motley Fool
EV Market: Is Mirum Pharmaceuticals Inc impacted by rising rates2025 Winners & Losers & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Aug PreEarnings: Is Tronox Holdings plc impacted by rising ratesIndex Update & Trade Opportunity Analysis - baoquankhu1.vn
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $123.00 at Morgan Stanley - MarketBeat
Chronic hepatitis D market set for steady growth as pipeline inches forward - The Pharma Letter
H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why? - Finviz
11 Best Stocks to Buy for Investment - Insider Monkey
Subdued Growth No Barrier To Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) With Shares Advancing 25% - simplywall.st
HC Wainwright Has Negative Outlook of MIRM FY2027 Earnings - MarketBeat
Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026 - AOL.com
Heron Patrick J buys Mirum Pharmaceuticals shares worth $8.99m By Investing.com - Investing.com UK
1.12%
0.87%
자본화:
|
볼륨(24시간):